About Salmedix
Salmedix is a company based in San Diego (United States) founded in 2000 was acquired by Cephalon in May 2005. Salmedix has raised $72.5 million across 3 funding rounds from investors including ARE, Orbimed and Cephalon. Salmedix operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Salmedix
Salmedix has successfully raised a total of $72.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in October 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Salmedix
Salmedix has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Orbimed and Cephalon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked |
Investor details for Salmedix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Salmedix
Investment portfolio details for Salmedix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Salmedix
Detailed financials for Salmedix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Salmedix Comparisons
Peer comparison for Salmedix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Salmedix
Salmedix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Monoclonal antibody therapies for pediatric leukemia are developed.
|
Detailed competitors of Salmedix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Salmedix
Complete news archive for Salmedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Salmedix
Salmedix was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Salmedix is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Salmedix is a funded company, having raised a total of $72.5M across 3 funding rounds to date.
Salmedix was founded in 2000 and is based in San Diego, United States. Operations are conducted in the biotechnology sector, where compounds for treating hematologic cancers are developed. Prior human clinical data is leveraged in these compounds to enable a shorter and less costly development timeline. The lead pipeline product, SDX-105, is targeted at non-Hodgkins lymphoma.
Salmedix's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Salmedix has 19 investors. Key investors include ARE, Orbimed, Cephalon, Bemberg Capital, and H.I.G. Capital.